CLINICAL TRIAL SUMMARY

MDACC Study No:2006-0014 (clinicaltrials.gov NCT No: NCT00479128)
Title:Phase I Two-Dimensional Dose-Finding Study of Bortezomib in Combination with Gemcitabine/Doxorubicin in Metastatic Surgically Unresectable Urothelial Cancer or Other Solid Tumors.
Principal Investigator:Arlene Siefker-Radtke
Treatment Agent:Bortezomib; Doxorubicin; Gemcitabine
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of GemzarŽ (gemcitabine) and AdriamycinŽ (doxorubicin) that can be given
together with VelcadeŽ (bortezomib) in patients with urothelial cancer or other
solid tumors.

Hide details for General InformationGeneral Information

Disease Group:Bladder
Phase of Study:Phase I
Treatment Agents:Bortezomib
Doxorubicin
Gemcitabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Chemotherapy will be given as an outpatient.
Supported By:N/A
Return Visit:Approximately every 2 weeks while on chemotherapy.
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Arlene Siefker-Radtke
Dept:Genitourinary Medical Oncology
For Clinical Trial Enrollment:713-792-2830
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults